Circle Method Observational Project - Non-interventional, Retrospective, Multicenter Data Collection

NCT ID: NCT05844969

Last Updated: 2025-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-01

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this non-interventional, retrospective data analysis is to validate the circle method for patients with bicuspid aortic heart valves undergoing transcatheter aortic heart valve implantation (TAVI).

The main aims are:

* to assess whether patients with bicuspid aortic valves that received a TAVI suffered from fewer complications

* if valve size was identical to the one determined using the circle method compared to
* a case where circle method derived valve size is different from the actually implanted valve
* to develop recommendations on how to size the valve using the circle method.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The bicuspid aortic valve (BAV) is the most common heart valve abnormality and is associated with a number of cardiac complications, including infective endocarditis, aortic dissection, aortic dilatation, and the development of severe aortic stenosis (AS). Due to its anatomical characteristics BAV has been considered a contraindication to transcatheter aortic valve implantation (TAVI), a standard treatment of AS. However, several recent trials have presented promising results indicating TAVI to be a safe alternative to surgery for low risk patients and more patients with BAV have been considered for TAVI.

There are several sizing techniques for TAVI in BAV, including an annular sizing, a supra-annular sizing, and a balloon sizing, yet there is still no consensus on the most appropriate technique. Although annular sizing remains the major approach in most patients with BAV, some BAV anatomies may profit from the supra-annular sizing. Recently published consensus for sizing and positioning the balloon-expandable Edwards SAPIEN 3 transcatheter heart valve (THV) in BAV describes the anatomical features that influence sizing optimization. The novel circle technique has also been proposed in the presence of the unique anatomical factors and sizing at the supra-annular level. This method is particularly helpful for visually identifying anatomic features, indicating the sealing zone at the commissures, visually reassuring of the size and position, and treating patients with large annuli. Currently, there are limited data validating the circle method for identifying sizing and positioning for TAVI in BAV patients.

In this non-interventional, retrospective, multicenter data collection and analysis we aim to validate the circle method for sizing and positioning in bicuspid aortic valves.

Due to the non-interventional character of the project, no additional burden will be put on the patients eligible for inclusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Stenosis With Bicuspid Valve

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with bicuspid aortic valves who underwent aortic valve replacement with a balloon expandable valve (SAPIEN 3 / Ultra)
* Computed Tomography data available

Exclusion Criteria

\- none
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role collaborator

Institut für Pharmakologie und Präventive Medizin

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierluigi Costanzo, Dr.

Role: STUDY_DIRECTOR

Royal Papworth Hospital NHS Foundation Trust

Ioannis Lianos, Dr.

Role: PRINCIPAL_INVESTIGATOR

Guy's and St Thomas NHS Foundation Trust

Tiffany Patterson, Dr.

Role: PRINCIPAL_INVESTIGATOR

Guy's and St Thomas NHS Foundation Trust

Timothy Bagnall, Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospitals Sussex NHS Foundaton Trust

Angie Ghattas, Dr.

Role: PRINCIPAL_INVESTIGATOR

Golden Jubilee National Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Papworth Hospital NHS Foundation Trust

Cambridge, , United Kingdom

Site Status

Golden Jubilee National Hospital

Clydebank, , United Kingdom

Site Status

Guy's and St Thomas NHS Foundation Trust

London, , United Kingdom

Site Status

University Hospitals Sussex NHS Foundation Trust

Worthing, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marie F Zielinski

Role: CONTACT

+49 4471 850 3326

Claudia M Lüske, Dr.

Role: CONTACT

+49 4471 850 3324

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pierluigi Costanzo, Dr.

Role: primary

Angie Ghattas, Dr.

Role: primary

Ioannis Lianos, Dr.

Role: primary

Tiffany Patterson, Dr.

Role: backup

David Hildick-Smith, Prof. Dr.

Role: primary

Timothy Bagnall

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMOP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Nordic Aortic Valve Intervention Trial
NCT01057173 ACTIVE_NOT_RECRUITING NA